Optically active amines. XIX. Circular dichroism of ortho-, meta-, and para-substituted .beta.-phenylalkylamine hydrochlorides. Further applications of the salicylidenimino chirality rule
[EN] SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1<br/>[FR] AGONISTES À PETITES MOLÉCULES DE RÉCEPTEUR DE NEUROTENSINE 1
申请人:SANFORD BURNHAM MED RES INST
公开号:WO2014100501A1
公开(公告)日:2014-06-26
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
(R)-Amination mediated by (R)-specific ω-transaminases generally requires costly d-alanine in excess to obtain the desired chiralamines in high yield. Herein, a one-pot, trienzymatic cascade comprising an (R)-specific ω-transaminase, an amine dehydrogenase, and a formate dehydrogenase was developed for the economical and eco-friendly synthesis of (R)-chiral amines. Using inexpensive ammonium formate as the
AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
申请人:CHEMAPOTHECA, LLC
公开号:US20180243241A1
公开(公告)日:2018-08-30
The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
申请人:Pfizer Inc.
公开号:US20020123490A1
公开(公告)日:2002-09-05
The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.
[EN] METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LA PRÉPARATION DE CONJUGUÉS D'AMPHÉTAMINE ET DE SELS DE CEUX-CI
申请人:CAMBREX CHARLES CITY INC
公开号:WO2010148305A1
公开(公告)日:2010-12-23
The invention provides methods and compositions for preparing amphetamine conjugates, such as lisdexamfetamine, homoarginine-D-amphetamine, and salts thereof. In one embodiment, the invention provides methods of preparing an amphetamine conjugate from a chloramphetamine intermediate.